John Q. Trojanowski, M.D., Ph.D., leadership roles include Director of the Institute on Aging, Director of the Alzheimer’s Disease Core Center, Director of Udall Parkinson’s Center and Co-Director of the Center for Neurodegenerative Disease Research at The University of Pennsylvania School of Medicine, Philadelphia, PA.. He is also Co-director of the Marian S. Ware Alzheimer Drug Discovery Program there.
For great than 15 years, Dr. Trojanowski has conducted research on AD, PD, motor neuron disease, dementia with Lewy bodies (DLB), frontotemporal dementias (FTDs) and related disorders. Most of his greater than 500 publications focus on the pathobiology of neurodegenerative disorders, especially the role of abnormal filamentous protein aggregates in these diseases.
He has received numerous awards for his research including: a MERIT Award (1986-1994) from the National Institutes of Health (NIH), the Metropolitan Life Foundation Promising Investigator Award for Alzheimer's Disease Research (1991), the Metropolitan Life Foundation Award for Alzhiemer's Disease Research (1996), the Potamkin Prize for Research in Pick's, Alzheimer's and Related Diseases (1998), the first Pioneer Award from the Alzheimer's Association (1998), ISI Highly Cited Research 2000 (most highly cited neuroscientists for 1981-1999), the 2004 Irving Wright Award of Distinction of the American Federation for Aging Research, and the 2005 Rous-Whipple Award of the American Society for Investigative Pathology. He is on the editorial board of several neuroscience and pathology journals and has served and continues to serve on local and national aging research committees.
For great than 15 years, Dr. Trojanowski has conducted research on AD, PD, motor neuron disease, dementia with Lewy bodies (DLB), frontotemporal dementias (FTDs) and related disorders. Most of his greater than 500 publications focus on the pathobiology of neurodegenerative disorders, especially the role of abnormal filamentous protein aggregates in these diseases.
He has received numerous awards for his research including: a MERIT Award (1986-1994) from the National Institutes of Health (NIH), the Metropolitan Life Foundation Promising Investigator Award for Alzheimer's Disease Research (1991), the Metropolitan Life Foundation Award for Alzhiemer's Disease Research (1996), the Potamkin Prize for Research in Pick's, Alzheimer's and Related Diseases (1998), the first Pioneer Award from the Alzheimer's Association (1998), ISI Highly Cited Research 2000 (most highly cited neuroscientists for 1981-1999), the 2004 Irving Wright Award of Distinction of the American Federation for Aging Research, and the 2005 Rous-Whipple Award of the American Society for Investigative Pathology. He is on the editorial board of several neuroscience and pathology journals and has served and continues to serve on local and national aging research committees.
John Morris, MD, is the Harvey and Dorismae Hacker Friedman Distinguished Professor of Neurology, Professor of Pathology and Immunology, Professor of Physical Therapy, and Director of the Memory and Aging Project, and the Center for Aging at Washington University in St. Louis. He also is the Director and Principal Investigator of the National Institute on Aging (NIA)-funded Alzheimer's Disease Research Center.
Dr. Morris is also the Principal Investigator of two additional NIA program projects, "Healthy Aging and Senile Dementia," and "Antecedent Biomarkers for AD: The Adult Children Study." He directs Washington University's Harvey A. Friedman Center for Aging. In the Medical School's Department of Neurology, and serves as Head of the Dementia and Aging Section.
Dr. Morris received his B.A. from Ohio Wesleyan University, and his MD from the University of Rochester School of Medicine and Dentistry in Rochester, NY, in 1974.
Dr. Morris is a member of numerous scientific and advocacy organizations, including the Alzheimer's Association's Medical & Scientific Advisory Committee. He chairs the Clinical Task Force for the National Institute on Aging and its Alzheimer Disease Centers program. He is author or co-author of over 250 peer-reviewed journal articles and 50 chapters and reviews. He has received many honors, including the Lifetime Achievement Award from the Alzheimer's Association (2004), and the 2005 Potamkin Prize for Research in Pick's, Alzheimer's, and Related Disease from the American Academy of Neurology.
Dr. Morris is a member of numerous scientific and advocacy organizations, including the Alzheimer's Association's Medical & Scientific Advisory Committee. He chairs the Clinical Task Force for the National Institute on Aging and its Alzheimer Disease Centers program. He is author or co-author of over 250 peer-reviewed journal articles and 50 chapters and reviews. He has received many honors, including the Lifetime Achievement Award from the Alzheimer's Association (2004), and the 2005 Potamkin Prize for Research in Pick's, Alzheimer's, and Related Disease from the American Academy of Neurology.
Mark S. Forman, M.D., Ph.D., is currently Associate Director of Clinical Pharmacology at Merck Research Laboratories. At the time he appeared in the program Alzheimer’s Disease: Facing the Facts he was an Assistant Professor in Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine; Co-Director of the Neurodegenerative Disease Brain Bank at Penn’s Center for Neurodegenerative Disease Research, and Director of the Neuropathology Core at the University of Pennsylvania Alzheimer’s Disease Center
His research primarily focuses on molecular pathogenesis of the frontotemporal dementias (FTD) using cell culture and animal model systems.
Dr. Forman earned his B.S. in Molecular Biophysics & Biochemistry from Yale University, his MD from Duke University School of Medicine, and his Ph.D. from Rockefeller University, in Immunology. He completed a post doctoral fellowship, and a medical residency and fellowship in Laboratory Medicine and Pathology, and in Neuropathology, at the Hospital of the University of Pennsylvania.
His research primarily focuses on molecular pathogenesis of the frontotemporal dementias (FTD) using cell culture and animal model systems.
Dr. Forman earned his B.S. in Molecular Biophysics & Biochemistry from Yale University, his MD from Duke University School of Medicine, and his Ph.D. from Rockefeller University, in Immunology. He completed a post doctoral fellowship, and a medical residency and fellowship in Laboratory Medicine and Pathology, and in Neuropathology, at the Hospital of the University of Pennsylvania.
Ronald C. Petersen, Ph.D., M.D. is the Cora Kanow Professor of Alzheimer’s Disease Research and the Director of the Alzheimer’s Disease Research Center at the Mayo Clinic College of Medicine in Rochester, MN.
He received a Ph.D. in Experimental Psychology from the University of Minnesota in 1972, and served as a Research Psychologist at the U.S. Army Biomedical Research Laboratory in Edgewood, Maryland. He graduated from Mayo Clinic College of Medicine in 1980 and completed an internship in Medicine at Stanford University Medical Center. Upon completing a residency in Neurology at Mayo and a fellowship in Behavioral Neurology at Harvard University Medical School/Beth Israel Hospital in Boston, Massachusetts, Dr. Petersen joined the staff of the Mayo Clinic in 1986.
He has authored over 250 peer-reviewed articles on memory disorders, aging, and Alzheimer’s disease. He has edited four books, including the Mayo Clinic Guide to Alzheimer’s Disease. He has served on numerous advisory boards for the American Board of Psychiatry and Neurology, the National Institutes of Health, including the Board of Scientific Counselors of the National Institute on Aging, and is currently the Chair of the Medical and Scientific Advisory Council of the Alzheimer’s Association.
Among multiple prestigious awards, Dr. Petersen is co recipient of the 2005 Potamkin Prize for Research in Picks, Alzheimer’s and Related Disorders of the American Academy of Neurology. He also received the inaugural Ronald and Nancy Reagan Research Institute Award in 2004 from the Alzheimer’s Association and the inaugural Leon Thal Prize of the Lou Ruvo Brain Institute in 2007. His current research focuses on the study of normal aging, mild cognitive impairment, and Alzheimer’s disease.
He received a Ph.D. in Experimental Psychology from the University of Minnesota in 1972, and served as a Research Psychologist at the U.S. Army Biomedical Research Laboratory in Edgewood, Maryland. He graduated from Mayo Clinic College of Medicine in 1980 and completed an internship in Medicine at Stanford University Medical Center. Upon completing a residency in Neurology at Mayo and a fellowship in Behavioral Neurology at Harvard University Medical School/Beth Israel Hospital in Boston, Massachusetts, Dr. Petersen joined the staff of the Mayo Clinic in 1986.
He has authored over 250 peer-reviewed articles on memory disorders, aging, and Alzheimer’s disease. He has edited four books, including the Mayo Clinic Guide to Alzheimer’s Disease. He has served on numerous advisory boards for the American Board of Psychiatry and Neurology, the National Institutes of Health, including the Board of Scientific Counselors of the National Institute on Aging, and is currently the Chair of the Medical and Scientific Advisory Council of the Alzheimer’s Association.
Among multiple prestigious awards, Dr. Petersen is co recipient of the 2005 Potamkin Prize for Research in Picks, Alzheimer’s and Related Disorders of the American Academy of Neurology. He also received the inaugural Ronald and Nancy Reagan Research Institute Award in 2004 from the Alzheimer’s Association and the inaugural Leon Thal Prize of the Lou Ruvo Brain Institute in 2007. His current research focuses on the study of normal aging, mild cognitive impairment, and Alzheimer’s disease.
Dorene Rentz, PsyD., is an Assistant Professor of Neurology at Harvard Medical School and a Senior Neuropsychologist in the Division of Cognitive and Behavioral Neurology’s Memory Disorders Unit at the Brigham and Women’s Hospital and a Research Neuropsychologist at the Massachusetts General Hospital. Dr. Rentz also serves as the Co-Director of the Clinical Research, Memory Disorders Unit, which offers experimental treatments for Alzheimer’s disease and provides a platform for Investigator Initiated research studies in normal aging and Mild Cognitive Impairment.
As a researcher, Dr. Rentz has been the recipient of several grants and had first author publications for her research involving the neuropsychological detection of early Alzheimer’s disease in highly intelligent elders. With her collaborators, Dr. Reisa Sperling and Dr. Keith Johnson; she is utilizing the latest technologies of fMRI and amyloid imaging on PET to explore the impact of cognitive reserve in disambiguating Alzheimer’s disease from normal aging. In addition to the above work, Dr. Rentz provides clinical care and support to families who suffer the devastating effects of dementia.
As a researcher, Dr. Rentz has been the recipient of several grants and had first author publications for her research involving the neuropsychological detection of early Alzheimer’s disease in highly intelligent elders. With her collaborators, Dr. Reisa Sperling and Dr. Keith Johnson; she is utilizing the latest technologies of fMRI and amyloid imaging on PET to explore the impact of cognitive reserve in disambiguating Alzheimer’s disease from normal aging. In addition to the above work, Dr. Rentz provides clinical care and support to families who suffer the devastating effects of dementia.
Hugh Hendrie, M.B., Ch.B., DSc., is Professor of Psychiatry in the Department of Psychiatry; Research Scientist at the Indianna University Center on Aging Research; and Co-Director of the Center for Alzheimer’s Disease and Related Neuropsychiatric Disorders, Indiana University School of Medicine. In July of 2000, he retired as Chairman of tha Department, having held that position for 25 years. Dr. Hendrie received his M.B. Ch.B. at the Faculty of Medicine, University of Glasgow; a Diploma in Psychiatry from the University of Manitoba; and an M.S. from Wayne State University. He received his Doctor of Science degree in Medicine from the University of Glasgow in 2002.
He is co-principal investigator of a multi-disciplinary group of researchers conducting international comparative studies of dementia and Alzheimer’s disease in Nigeria and the United States supported by the National Institute on Aging. He also chaired a National Institutes of Health committee on factors influencing cognitive and emotional health, and is on the steering committee of the Center for Disease Control/Alzheimer Association Healthy Brain Initiative Research Policy group.
He is co-principal investigator of a multi-disciplinary group of researchers conducting international comparative studies of dementia and Alzheimer’s disease in Nigeria and the United States supported by the National Institute on Aging. He also chaired a National Institutes of Health committee on factors influencing cognitive and emotional health, and is on the steering committee of the Center for Disease Control/Alzheimer Association Healthy Brain Initiative Research Policy group.
Robert Astur, Ph.D. is Director of the Virtual Reality Laboratory at the Olin Neuropsychiatry Research Center at the Institute of Living at Hartford Hospital, Hartford, CT, and Assistant Clinical Professor in the Department of Psychiatry at Yale University.
Dr. Astur has considerable experience examining memory function in a variety of species including rodents, monkeys, chimpanzees, orangutans, and dogs. He has been a pioneer and innovator in extending the memory tests used in nonhumans to humans using virtual reality. Accordingly, his work has spawned a variety of virtual reality spatial memory tests used to assess hippocampus function in people at risk for Alzheimer’s disease. Moreover, his laboratory has developed a driving simulator designed to assess driving safety and skill in elderly populations to allow for people with progressive illnesses to drive safely as long as possible.
He received a BS in Neuroscience from the University of Rochester and his PhD in Cognitive Neuroscience from the University of New Mexico. He was a postdoctoral scholar at Cal Tech, where he initiated a research program recording single neuronal activity from humans during memory tasks. At Yale, he worked in using functional magnetic resonance imaging (MRI) to examine memory function in psychiatric populations.
Dr. Astur has published extensively in areas relating to the neurobiology of memory. He is funded as the principal investigator on a NIDA Cutting Edge Basic Research Award, various Hartford Hospital internal grants, and as a co-investigator on multiple National Institute of Health major research grants.
Dr. Astur has considerable experience examining memory function in a variety of species including rodents, monkeys, chimpanzees, orangutans, and dogs. He has been a pioneer and innovator in extending the memory tests used in nonhumans to humans using virtual reality. Accordingly, his work has spawned a variety of virtual reality spatial memory tests used to assess hippocampus function in people at risk for Alzheimer’s disease. Moreover, his laboratory has developed a driving simulator designed to assess driving safety and skill in elderly populations to allow for people with progressive illnesses to drive safely as long as possible.
He received a BS in Neuroscience from the University of Rochester and his PhD in Cognitive Neuroscience from the University of New Mexico. He was a postdoctoral scholar at Cal Tech, where he initiated a research program recording single neuronal activity from humans during memory tasks. At Yale, he worked in using functional magnetic resonance imaging (MRI) to examine memory function in psychiatric populations.
Dr. Astur has published extensively in areas relating to the neurobiology of memory. He is funded as the principal investigator on a NIDA Cutting Edge Basic Research Award, various Hartford Hospital internal grants, and as a co-investigator on multiple National Institute of Health major research grants.
Reisa Sperling, M.D., M.MSc. is the Director of Clinical Research at the Memory Disorders Unit, Brigham and Women’s Hospital, and an Assistant Professor of Neurology at Harvard Medical School. Dr. Sperling is the Co-Director of the Neurology Clinical Trials Service at the Brigham, Massachusetts General Hospital and the Harvard Center for Neurodegeneration and Repair. She also serves on the Steering Committee of the Alzheimer Disease Cooperative Study, an NIA funded consortium, and on the Editorial Board of Alzheimer’s Disease and Associated Disorders. She received her M.D. degree at Harvard Medical School, and a Master’s Degree in Clinical Investigation from a joint program of Harvard and the Massachusetts Institute of Technology.
Dr. Sperling’s research is focused on the use of functional MRI to study the alterations in neural substrate responsible for memory impairment in early Alzheimer’s disease, and the development of fMRI as a surrogate marker of pharmacological efficacy in clinical trials for AD.
Dr. Sperling’s research is focused on the use of functional MRI to study the alterations in neural substrate responsible for memory impairment in early Alzheimer’s disease, and the development of fMRI as a surrogate marker of pharmacological efficacy in clinical trials for AD.
Dr. Bennett is the Robert C. Borwell Professor of Neurological Sciences and director of the Rush University Alzheimer’s Disease Center. Dr. Bennett received the degree of bachelor of science with high distinction and high honors in physiology from the University of Michigan, Ann Arbor, in 1979. He earned his doctorate in medicine from Rush Medical College in 1984.
Following his medical internship, Dr. Bennett returned to Rush for residency training in neurology and a research fellowship in dementia, which he completed in 1989. Dr. Bennett was board certified in neurology in 1990. Dr. Bennett is nationally known for his research into the causes, treatment and prevention of Alzheimer’s disease and other neurologic conditions such as parkinsonism, cerebrovascular disease, and motor neuron disease. His primary research interest is the neurobiologic mechanisms whereby risk factors lead to the development of Alzheimer’s disease and other age-related neurologic conditions. Dr. Bennett is principal investigator of several studies funded by the National Institute on Aging, including the Rush Alzheimer’s Disease Core Center, the Religious Orders Study and the Memory and Aging Project.
He also directs the Regional Alzheimer’s Disease Assistance Center for Northern Illinois for the Illinois Department of Public Health. He has published more than 140 manuscripts and book chapters.
Following his medical internship, Dr. Bennett returned to Rush for residency training in neurology and a research fellowship in dementia, which he completed in 1989. Dr. Bennett was board certified in neurology in 1990. Dr. Bennett is nationally known for his research into the causes, treatment and prevention of Alzheimer’s disease and other neurologic conditions such as parkinsonism, cerebrovascular disease, and motor neuron disease. His primary research interest is the neurobiologic mechanisms whereby risk factors lead to the development of Alzheimer’s disease and other age-related neurologic conditions. Dr. Bennett is principal investigator of several studies funded by the National Institute on Aging, including the Rush Alzheimer’s Disease Core Center, the Religious Orders Study and the Memory and Aging Project.
He also directs the Regional Alzheimer’s Disease Assistance Center for Northern Illinois for the Illinois Department of Public Health. He has published more than 140 manuscripts and book chapters.
Thomas Perls, M.D., is the founder and director of the New England Centenarian Study, the largest study of centenarians in the world. A significant portion of the study is devoted to understanding why centenarians delay or escape Alzheimer’s disease and other brain disorders. He is the author of numerous scientific and popular press articles and books, including Living to 100.
Dr. Perls completed his undergraduate degree in Biology at Pitzer College in Claremont , California . He graduated from the University of Rochester School of Medicine in 1986, followed by internship in internal medicine at Harbor UCLA Medical Center and a 3 year Geriatrics Fellowship at Harvard Medical School. He joined the staff at New England Deaconess Hospital and later Beth Israel Deaconess Medical Center as Assistant Professor at Harvard Medical School . He joined Boston University School of Medicine’s Geriatrics Section in 2001 as an Associate Professor. Dr. Perls is board certified in Internal Medicine with special qualifications in Geriatrics and he is a Fellow of the American College of Physicians.
Dr. Perls completed his undergraduate degree in Biology at Pitzer College in Claremont , California . He graduated from the University of Rochester School of Medicine in 1986, followed by internship in internal medicine at Harbor UCLA Medical Center and a 3 year Geriatrics Fellowship at Harvard Medical School. He joined the staff at New England Deaconess Hospital and later Beth Israel Deaconess Medical Center as Assistant Professor at Harvard Medical School . He joined Boston University School of Medicine’s Geriatrics Section in 2001 as an Associate Professor. Dr. Perls is board certified in Internal Medicine with special qualifications in Geriatrics and he is a Fellow of the American College of Physicians.
Carl Cotman, Ph.D., is a Professor of Neurology and Neurobiology and Behavior at the University of California, Irvine where he began his career in 1968. Since 1995 he has also been Director of the Institute for Brain Aging and Dementia at UCI. He has chaired the Scientific Advisory Council of the Alzheimer’s Association and is a member of numerous professional associations and committees. Dr. Cotman also serves on editorial boards such as the Journal of Alzheimer’s Disease and Other Dementias and has authored or co-authored nine books and over 696 articles in the fields of neurobiology, memory and cognition, and the basic mechanisms causing brain dysfunction in aging and the development of Alzheimer’s.
Dr. Cotman was recently award the Lifetime Achievement Award by the International Alzheimer’s Association; is included in the 2007 list of ISI Highly Cited Researchers; Co-Recipient of the Reeve-Irvine Research Medal for 2005 for breakthrough studies in the understanding of the mechanisms underlying adult neuroplasticity. Dr. Cotman also received the UCI Medal in 2004 for recognition of his contributions to the field of science, teaching, and community service.
Dr. Cotman received his B.A. in Chemistry from Wooster College; and M.A. in Analytical Chemistry from Wesleyan University and a Ph.D in Biochemistry from Indiana University.
Dr. Cotman was recently award the Lifetime Achievement Award by the International Alzheimer’s Association; is included in the 2007 list of ISI Highly Cited Researchers; Co-Recipient of the Reeve-Irvine Research Medal for 2005 for breakthrough studies in the understanding of the mechanisms underlying adult neuroplasticity. Dr. Cotman also received the UCI Medal in 2004 for recognition of his contributions to the field of science, teaching, and community service.
Dr. Cotman received his B.A. in Chemistry from Wooster College; and M.A. in Analytical Chemistry from Wesleyan University and a Ph.D in Biochemistry from Indiana University.
William H. Thies, Ph.D., is vice president of Medical and Scientific Relations at the Alzheimer’s Association. At the Association, Dr. Thies oversees the world’s largest private, nonprofit Alzheimer’s disease research grants program. Under his direction, the annual grants budget has doubled, and the program has designated special focus areas targeting the relationship between cardiovascular risk factors and Alzheimer’s disease; caregiving and care systems; and research involving diverse populations.
Thies led the integration into the Alzheimer’s Association of the International Conference on Alzheimer’s Disease (ICAD). Thies also spearheaded initiation of the International Conference on Prevention of Dementia. He played a key role in launching the Association’s peer-reviewed journal, Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, and in establishing the Research Roundtable, a consortium of senior scientists from industry, academia and government who meet regularly to explore topics of mutual interest in drug discovery and common barriers to progress.
Thies earned a B.A. in biology from Lake Forest College, Lake Forest, Ill., and a Ph.D. in pharmacology from the University of Pittsburgh, School of Medicine.
Thies led the integration into the Alzheimer’s Association of the International Conference on Alzheimer’s Disease (ICAD). Thies also spearheaded initiation of the International Conference on Prevention of Dementia. He played a key role in launching the Association’s peer-reviewed journal, Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, and in establishing the Research Roundtable, a consortium of senior scientists from industry, academia and government who meet regularly to explore topics of mutual interest in drug discovery and common barriers to progress.
Thies earned a B.A. in biology from Lake Forest College, Lake Forest, Ill., and a Ph.D. in pharmacology from the University of Pittsburgh, School of Medicine.
Clifford R. Jack, Jr., M.D., is a professor of radiology at the Mayo Clinic College of Medicine, and the Alexander Family Professor of Alzheimer’s Disease Research at the Mayo Clinic.
He is a clinician investigator with 100% effort devoted to research. His research group is engaged in developing and validating magnetic resonance imaging techniques for diagnosis and measuring progression of Alzheimer’s disease and related disorders. Dr Jack’s research group also collaborates with a number of investigators outside Mayo, including serving as the MRI Core of the Alzheimer’s Neuroimaging Initiative.
Dr. Jack received the B.S. degree in biology, magna cum laude, from the University of Michigan and attended medical school at Wayne State University School of Medicine. He completed a fellowship in neuroradiology at Mayo Clinic. He was the 2007 recipient of the American Society of Neuroradiology (Neuroradiology Education and Research Foundation) Award for Outstanding Contributions in Research, and the 2008 Co-recipient of the Potamkin Prize for Research in Pick’s, Alzheimer’s and Related Diseases, American Academy of Neurology. He is certified by the American Board of Radiology in diagnostic radiology and neuroradiology.
He is a clinician investigator with 100% effort devoted to research. His research group is engaged in developing and validating magnetic resonance imaging techniques for diagnosis and measuring progression of Alzheimer’s disease and related disorders. Dr Jack’s research group also collaborates with a number of investigators outside Mayo, including serving as the MRI Core of the Alzheimer’s Neuroimaging Initiative.
Dr. Jack received the B.S. degree in biology, magna cum laude, from the University of Michigan and attended medical school at Wayne State University School of Medicine. He completed a fellowship in neuroradiology at Mayo Clinic. He was the 2007 recipient of the American Society of Neuroradiology (Neuroradiology Education and Research Foundation) Award for Outstanding Contributions in Research, and the 2008 Co-recipient of the Potamkin Prize for Research in Pick’s, Alzheimer’s and Related Diseases, American Academy of Neurology. He is certified by the American Board of Radiology in diagnostic radiology and neuroradiology.
Christopher M. Clark, M.D., a board certified neurologist, is Associate Professor of Neurology, and director of the recently initiated Center of Excellence for Research on Neurodegenerative Diseases at the University of Pennsylvania. After 17 years, he retired as Director of the PENN Memory Center in 2008. He is a Fellow of the University of Pennsylvania 's Institute on Aging, and has been a faculty member since 1989.
Dr. Clark has spent most of his career studying Alzheimer's disease. He is the current Principal Investigator of a National Institute of Aging grant, and an investigator for numerous other studies including the landmark Alzheimer's Disease Neuroimaging Initiative (ADNI).
His research interests focus on Alzheimer's disease and the development of diagnostically specific markers, the identification and evaluation of new treatments, the development of new instruments to measure rates of change, and studies of the relationship between Parkinson's disease and Alzheimer's disease.
Dr. Clark has spent most of his career studying Alzheimer's disease. He is the current Principal Investigator of a National Institute of Aging grant, and an investigator for numerous other studies including the landmark Alzheimer's Disease Neuroimaging Initiative (ADNI).
His research interests focus on Alzheimer's disease and the development of diagnostically specific markers, the identification and evaluation of new treatments, the development of new instruments to measure rates of change, and studies of the relationship between Parkinson's disease and Alzheimer's disease.
The research of Mark A. Mintun, M.D., focuses on use of positron emission tomography (PET) in human subjects as a tool in the investigation of PET Amyloid Imaging to evaluate dementia risk. His current interest in the laboratory is Alzheimer’s Disease (AD) at the preclinical stage in which elevated levels of brain amyloid protein and accumulation of beta-amyloid deposits foreshadow the gradual onset of neuronal dysfunction, cell loss and dementia. In addition to conducting his own NIH-funded research projects at Washington University in St. Louis School of Medicine, Dr. Mintun is Director of the Center for Clinical Imaging Research and Research Development, Principal Investigator of the NINDS Center Core for Brain Imaging, and Core Director of the Neuroimaging Core of the Human Aging and Senile Dementia Program Project.
Dr. Mintun’s received a medical degree and research fellowship training in neurology, followed by residency training in nuclear medicine from Washington University School of Medicine. Dr. Mintun studied various applications of PET technology in the laboratories of Michel M. Ter-Pogossian, PhD, and Marcus E. Raichle, MD.
Dr. Mintun’s received a medical degree and research fellowship training in neurology, followed by residency training in nuclear medicine from Washington University School of Medicine. Dr. Mintun studied various applications of PET technology in the laboratories of Michel M. Ter-Pogossian, PhD, and Marcus E. Raichle, MD.
For the past 12 years, Anne Fagan, Ph.D., has investigated fluid biomarkers of Alzheimer’s disease, with an emphasis on early stage and preclinical (antecedent) detection. Anne serves as the Biomarker Core Leader and the PI or co-investigator on the biomarker portions of two program project grants at Washington University investigating brain and cognitive health during mid-life, normal aging and dementia. She is also the Biomarker Core Leader for a newly funded international study investigating biomarkers in autosomal-dominant forms of AD.
Dr. Fagan received her B.A. in Psychobiology from Wellesley College (’84), her Ph.D. in Neuroscience from the University of California at San Diego (’92) and is currently a Research Associate Professor in the Department of Neurology at Washington University in St. Louis, a Washington University Alzheimer’s Disease Research Center Investigator and faculty member of the Hope Center for Neurological Disorders.
Dr. Fagan is a member of the Society for Neuroscience, the St. Louis Chapter of Women in Neuroscience, and the Academic Women's Network at Washington University . She is the 2006 recipient of the Alzheimer's Disease Neuroimaging Award (New Investigator) from the Alzheimer's Association, and the recipient of the 2007 Annals of Neurology Prize for Distinguished Contribution to Clinical Neuroscience (“Highest Impact Paper”) for her work on the relationship between cerebrospinal fluid biomarkers and brain amyloid imaging.
Dr. Fagan received her B.A. in Psychobiology from Wellesley College (’84), her Ph.D. in Neuroscience from the University of California at San Diego (’92) and is currently a Research Associate Professor in the Department of Neurology at Washington University in St. Louis, a Washington University Alzheimer’s Disease Research Center Investigator and faculty member of the Hope Center for Neurological Disorders.
Dr. Fagan is a member of the Society for Neuroscience, the St. Louis Chapter of Women in Neuroscience, and the Academic Women's Network at Washington University . She is the 2006 recipient of the Alzheimer's Disease Neuroimaging Award (New Investigator) from the Alzheimer's Association, and the recipient of the 2007 Annals of Neurology Prize for Distinguished Contribution to Clinical Neuroscience (“Highest Impact Paper”) for her work on the relationship between cerebrospinal fluid biomarkers and brain amyloid imaging.
Daniel Skovronsky, M.D., Ph.D., founded Avid Radiopharmaceuticals in late 2004. Dr. Skovronsky has more than 20 peer reviewed publications and is principle investigator on four funded NIH small business grants on Alzheimer’s disease research and Diabetes. Prior to establishing Avid, Dr. Skovronsky served as Scientific Director of High Throughput Screening at the Center for Neurodegenerative Disease Research at the University of Pennsylvania. Dr. Skovronsky trained as a resident in Pathology and completed a fellowship in Neuropathology at the Hospital of the University of Pennsylvania.
Dr. Skovronsky received his M.D. and Ph.D. from the University of Pennsylvania. His undergraduate training in molecular biochemistry was at Yale University.
Dr. Skovronsky is a leader in the molecular imaging community. He has given numerous invited talks and is the recipient of many local and national awards. He was named by the Philadelphia Business Journal as a “Forty under Forty” business leaders in the region in 2006 and by PharmaVoice magazine as one of the 100 top pharmaceutical business leaders in 2007. Avid Radiopharmaceuticals was named the Life Sciences Startup Company of the Year at 2007 Eastern Technology Council and received the 2007 Frost & Sullivan Molecular Imaging Technology Innovation of the Year award.
Dr. Skovronsky received his M.D. and Ph.D. from the University of Pennsylvania. His undergraduate training in molecular biochemistry was at Yale University.
Dr. Skovronsky is a leader in the molecular imaging community. He has given numerous invited talks and is the recipient of many local and national awards. He was named by the Philadelphia Business Journal as a “Forty under Forty” business leaders in the region in 2006 and by PharmaVoice magazine as one of the 100 top pharmaceutical business leaders in 2007. Avid Radiopharmaceuticals was named the Life Sciences Startup Company of the Year at 2007 Eastern Technology Council and received the 2007 Frost & Sullivan Molecular Imaging Technology Innovation of the Year award.
